DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown Sells 13,000 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares of the company’s stock, valued at $7,432,268.76. This trade represents a 10.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

DexCom Stock Performance

NASDAQ DXCM opened at $70.69 on Friday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a market capitalization of $27.62 billion, a P/E ratio of 49.43, a PEG ratio of 2.30 and a beta of 1.28. The business has a 50 day moving average price of $83.99 and a 200 day moving average price of $76.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Several hedge funds have recently bought and sold shares of the stock. Covestor Ltd boosted its holdings in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares during the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of DexCom by 1.0% during the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after purchasing an additional 182 shares during the last quarter. Harbour Investments Inc. boosted its holdings in shares of DexCom by 8.8% during the third quarter. Harbour Investments Inc. now owns 12,895 shares of the medical device company’s stock worth $864,000 after purchasing an additional 1,046 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in shares of DexCom by 129.1% during the third quarter. GSA Capital Partners LLP now owns 10,268 shares of the medical device company’s stock worth $688,000 after purchasing an additional 5,787 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in shares of DexCom during the third quarter worth $221,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Morgan Stanley boosted their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Canaccord Genuity Group boosted their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.